Clopi

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopi

Quick Facts

Property Description
Active ingredient Clopidogrel (as Clopidogrel bisulfate)
Form Film-coated tablet (Oral preparation)
Pharmacological class Antiplatelet Agent / Antithrombotic Drug
General purpose Prevention of blood clot formation
Origin Synthetic compound (Prescription-only Pro-drug)

Defining Clopi: A Foundation in Antithrombotic Therapy

Clopi is an oral, prescription-only medication containing the active ingredient Clopidogrel, which is classified as an Antiplatelet Agent. The medication is chemically identified as a Thienopyridine derivative, a synthetic compound distinguished by its mechanism that achieves platelet stickiness reduction. Clopidogrel is designated as an Antithrombotic Drug used to reduce the risk of harmful internal blood clots (thrombi). Clopidogrel is an established core component of maintenance therapy, focusing on long-term blood clot prevention to ensure continuous, free-flowing circulation.

Composition and Origin: The Unique Pro-drug Mechanism

The medicine's composition features Clopidogrel (or Clopidogrel bisulfate) as the single-ingredient product, prepared as an oral, film-coated tablet. Clopidogrel is a synthetic compound derived through chemical synthesis, which contrasts with substances of natural origin. A key differentiating factor is its functional classification as a Pro-drug: the compound ingested is initially inert and requires a complex metabolic activation pathway in the liver. This metabolic dependency means the compound must be successfully transformed into its active state to achieve its therapeutic effect, distinguishing it from antiplatelet agents that are active immediately upon administration.

Essential Action: How Clopi Inhibits Platelet Activity

The fundamental physiological action of Clopi involves achieving platelet aggregation inhibition through the irreversible inhibition of the P2Y12 receptor on the platelet surface. The drug’s active metabolite chemically and permanently blocks this signaling pathway, which is normally activated by adenosine diphosphate (ADP) to trigger platelet aggregation. This irreversible binding mechanism is paramount to Clopi’s general purpose, providing reliable thrombosis reduction by preventing platelets from inappropriately clumping together within the circulatory system for the entire duration of the affected platelet's life.

What side effects are possible with Clopi?

Clopi: Possible side effects and safety information

The safety profile of Clopi (Clopidogrel) is defined by officially documented adverse reactions, primarily involving the risk of bleeding (hemorrhage), which is the most common adverse reaction reported in clinical use. The incidence of side effects is formally categorized in regulatory documents based on frequency.


Officially Classified Adverse Reactions

Frequency Classification Examples (Organ Systems Affected)
Common (1/100 to < 1/10) Haematoma, Epistaxis (nosebleed), Gastrointestinal hemorrhage, Diarrhoea, Abdominal pain, Dyspepsia, Bruising.
Uncommon (1/1,000 to < 1/100) Thrombocytopenia, Intracranial bleeding, Headache, Dizziness, Nausea, Gastritis, Rash, Haematuria (blood in urine).
Rare (1/10,000 to < 1/1,000) Vertigo, Retroperitoneal hemorrhage, Neutropenia.
Very Rare/Not Known Thrombotic Thrombocytopenic Purpura (TTP), Acute liver failure, Hepatitis, Anaphylactoid reactions, Acquired Haemophilia A, Pancreatitis.

Serious Reactions and Safety Considerations

The most clinically significant and serious documented reactions include major bleeding events, Intracranial Hemorrhage, and the rare, potentially fatal blood disorder Thrombotic Thrombocytopenic Purpura (TTP). The risk of bleeding is often reported during the first month of treatment.

Official regulatory labels establish several high-level safety restrictions. The medicine is contraindicated (should not be used) in patients with active pathological bleeding, such as a peptic ulcer or intracranial hemorrhage, and in individuals with severe hepatic impairment. Limited therapeutic experience is documented for use in patients with renal impairment or moderate hepatic disease. The safety structure emphasizes the potential for these adverse reactions as classified by authoritative health agencies.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Clopidogrel is documented by regulatory authorities to cause an exaggeration of the drug's antiplatelet effect. The primary clinical manifestation of over-administration is prolonged bleeding time, which may lead to bleeding complications. Officially reported signs may include the presence of unusual bruising or hemorrhage.

Official Overdose Concerns Regulatory Action Required
Prolonged Bleeding Time Seek immediate medical attention if bleeding is observed.
Bleeding Complications Appropriate therapy must be considered for any observed bleedings.

Regulatory guidance specifies immediate contact with emergency services (911) if the person has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Contacting the poison control helpline is also advised.

It is officially noted that no specific chemical antidote is known for reversing the effects of Clopidogrel overdosage. Management for severe or uncontrolled bleeding involves supportive measures, such as considering platelet transfusion to restore the ability to form clots, a procedure described in prescribing information. No population-specific overdose considerations are explicitly detailed in the regulatory Overdosage sections.

Therapeutic Uses of Clopi

Quick Facts

  • Acute Coronary Syndrome: Used to help reduce the risk of a heart attack and stroke.
  • Recent Events: Indicated for patients who have had a recent heart attack or recent stroke.
  • Peripheral Arterial Disease (PAD): Used to address associated vascular events.

Clopi is a medication prescribed to help manage and reduce the risk of serious cardiovascular and cerebrovascular events. Its primary role is to support the body’s management of blood flow.

The medication is frequently utilized in patients diagnosed with Acute Coronary Syndrome (ACS), a group of conditions that includes certain types of heart attack (myocardial infarction) and unstable angina. In these scenarios, Clopi is often used in combination with aspirin as part of a comprehensive management strategy.

Clopi is also indicated for reducing the potential for a subsequent heart attack or stroke in individuals with a medical history of these events. Furthermore, it is an established treatment option for managing vascular issues associated with Peripheral Arterial Disease (PAD). The therapeutic goal is to diminish the potential for harmful clot formation that may lead to complications. Treatment decisions should always be made in consultation with a qualified healthcare provider.

Eligibility and Restrictions for Use

Clopi (Clopidogrel) is an oral medication that can only be used by adult patients and is subject to several key exclusions as formally documented by regulatory authorities.

Official Eligibility Constraints

Classification Population or Condition
Contraindicated Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
Severe hepatic (liver) impairment
Hypersensitivity to Clopidogrel or its components
Use with Caution Renal impairment (limited therapeutic experience)
Moderate hepatic disease
Patients at risk of increased bleeding

Age and Physiological Restrictions

Use is not recommended in the pediatric population because the drug's safety and efficacy have not been established. For women who are pregnant or breastfeeding, regulatory labeling advises that Clopi is preferable not to use or that breastfeeding should not be continued, respectively. Furthermore, patients identified as CYP2C19 poor metabolizers should be given special consideration, as they may have a diminished antiplatelet effect.

What should I know about interactions with other medicines?

Clopi Interactions with other medicines and products

Official regulatory documents define the product's interaction profile through substances that affect its activity or increase bleeding risk.

Interactions Affecting Efficacy

Clopi's antiplatelet action depends on its conversion to an active form by the CYP2C19 enzyme. Medications that inhibit CYP2C19 reduce this conversion, resulting in diminished antiplatelet activity. Strong or moderate CYP2C19 inhibitors, such as omeprazole and esomeprazole, are explicitly stated in labeling to reduce this activity, and their co-administration is discouraged or should be avoided.

Interactions Increasing Bleeding Risk

Co-administration with several medicinal product categories is associated with an increased risk of bleeding due to additive effects on hemostasis or platelet function. The concomitant use of Clopi with oral anticoagulants (like warfarin) is generally not recommended due to a potential increase in bleeding intensity. Similarly, co-administration with other antiplatelet agents (e.g., aspirin) and non-steroidal anti-inflammatory drugs (NSAIDs) requires caution due to the increased risk of hemorrhage, particularly gastrointestinal blood loss.

Procedural and Population Considerations

For patients undergoing elective surgery with a major risk of bleeding, regulatory documents specify that Clopi should be discontinued five to seven days before the procedure. Additionally, official information notes that patients identified as CYP2C19 poor metabolizers exhibit reduced antiplatelet response, which is a recognized population-specific constraint on the drug's effectiveness.

Mechanism of Action

Pro-drug Activation and Metabolic Dependency

Clopidogrel is classified as a pro-drug that requires biotransformation to exert its antiplatelet effect. This process occurs primarily in the liver, where specific Cytochrome P450 enzymes ( CYP2C19) convert the parent compound into its active thiol metabolite. This metabolic step dictates the kinetics of the antiplatelet effect.

Irreversible P2Y12 Receptor Antagonism

The active metabolite forms a covalent, irreversible bond with the P2Y12 receptor on the surface of circulating platelets, functioning as a permanent antagonist. This highly specific interaction blocks the binding of the natural signaling molecule, Adenosine Diphosphate ( ADP), which is required for initiating platelet activation and aggregation.

️ Cascade Inhibition of Platelet Aggregation

By disrupting ADP signaling, the drug halts the intracellular cascade required to activate the platelet’s final clumping mechanism, the Glycoprotein GPIIb/ IIIa complex. This irreversible functional constraint leads to a sustained reduction in the platelet's capacity for aggregation, consistent with antiplatelet action for the entire lifespan of the treated platelet.

Dosage and Administration Information

How to Use Clopi

Clopi (Clopidogrel) is an oral medication administered as a film-coated tablet in strengths of 75 mg and 300 mg.


Dosing and Frequency Patterns

The standard pattern for Clopi is once daily for maintenance therapy across all approved uses. The initial regimen varies based on the clinical context:

Clinical Indication Administration Pattern
Recent MI, Stroke, or PAD 75 mg once daily, without a loading dose.
Non-ST-elevation ACS Single 300 mg oral loading dose, followed by 75 mg once daily.
ST-elevation MI 75 mg once daily; may be initiated with or without a 300 mg loading dose.

Administration Conditions and Constraints

The medication can be administered with or without food. The duration of therapy can extend up to 12 months following certain acute events. Initiating treatment without a loading dose will delay the establishment of the intended effect by several days.

Special Conditions:

  • Missed Dose: If a dose is missed by less than 12 hours of the scheduled time, it should be taken immediately. If missed by more than 12 hours, the dose should be skipped, and the next dose taken at the regular time; doubling the dose is not permitted.
  • Surgical Timing: Discontinuation is typically required 7 days prior to elective surgery.
  • Population Adjustment: For patients over 75 years of age with ST-elevation MI, the treatment must be initiated without a loading dose.
  • Co-Administration: The concomitant use of certain acid-reducing agents, such as Omeprazole or Esomeprazole, should be avoided.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clopidogrel (often referred to as Clopi) is an antiplatelet medication used to help manage the risk of serious cardiovascular events in individuals with specific conditions, such as recent heart attack, stroke, or established peripheral arterial disease. Clinical evidence from recent and large-scale studies continues to examine its effectiveness and safety profile, often in comparison to aspirin or other antiplatelet agents.


Key Findings in Cardiovascular Disease

Studies that enrolled patients following percutaneous coronary intervention (PCI)—a procedure to open blocked arteries—investigated the long-term use of clopidogrel alone versus aspirin alone after an initial period of combination therapy. In certain patient groups at high risk for recurrent events, clopidogrel was associated with a lower rate of the composite outcome of all-cause death, heart attack, or stroke, compared to aspirin monotherapy. This difference was largely driven by a reduction in the rate of heart attacks.

In a meta-analysis examining patients with established Coronary Artery Disease (CAD), clopidogrel monotherapy was evaluated against aspirin for secondary prevention. Over an average follow-up of several years, this analysis suggested that clopidogrel was associated with greater long-term reduction of cardiovascular events, including heart attack and stroke, than aspirin.


Safety and Comparative Risk

Across these large studies, the reported rate of major bleeding events was observed to be similar between the clopidogrel and aspirin monotherapy groups. This finding is significant given that increased antiplatelet activity can carry a higher potential for bleeding risk. The FDA has also reviewed long-term clinical trial data, concluding that clopidogrel use does not increase or decrease the overall risk of death in patients with, or at risk for, heart disease.

Key Studies & References

  1. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE)

Frequently Asked Questions (FAQ)

Common questions about Clopi (FAQ)


Q: What is Clopi most commonly prescribed for?

According to official information, Clopidogrel is approved to help lessen the chance of a recurrent heart attack or stroke in patients who have recently experienced one. It is also used for individuals with established peripheral arterial disease (PAD) and in the management of acute coronary syndrome (ACS). The goal is to help reduce the risk of harmful blood clots forming in these high-risk populations.


Q: Is Clopi the same as [Another popular antiplatelet drug]?

Official regulatory documents classify Clopidogrel as a P2Y12 platelet inhibitor and a member of the thienopyridine drug class. This classification defines its specific mechanism of action. While there are other antiplatelet drugs, Clopidogrel is a distinct chemical compound and is not the same as other medications in this category.


Q: Are there any foods or drinks I need to avoid while taking Clopi?

Official regulatory information states that Clopi can be taken with or without food. Generally, the official labels do not mandate avoiding specific foods while taking this medication.


Q: What are the signs of a serious problem while taking Clopi?

Serious side effects are rare but may occur. Official patient information indicates that symptoms such as a sudden change in mental status or speaking ability, fever, severe paleness, seizures, or yellowing of the eyes or skin should be reported immediately to a healthcare provider. These may be signs of a serious problem.


Q: Is Clopi safe for older adults?

Based on official reviews, studies have not shown geriatric-specific problems that would inherently limit the usefulness of this medication in older adults. Official prescribing information notes that typically, a general dosage adjustment is not needed based on age alone.


Q: Do I need to change my diet when starting Clopi?

Official guidance does not mandate a specific restrictive diet when starting Clopi. General patient guidelines often encourage maintaining a balanced diet, including whole grains, fruits, and vegetables.


Q: What is the difference between Clopi and warfarin?

Clopidogrel is classified as an antiplatelet medication, meaning it works by stopping platelets (a type of blood cell) from clumping together. Warfarin, by contrast, is an oral anticoagulant that works in the liver to prevent the formation of specific blood clotting factors. Although both affect the body's clotting system, their mechanisms of action are distinct.


Q: Why did my doctor prescribe Clopi after a heart attack?

The official use of this medication following a heart attack is for secondary prevention. This means it is used to lessen the chance of experiencing a subsequent major cardiovascular event, such as another heart attack or stroke.


Q: Can I drink alcohol in moderation while taking Clopi?

According to regulatory-based patient information, moderate alcohol use is generally regarded as safe while taking this medication. However, excessive consumption of alcohol may cause irritation to the stomach lining. Since the medication is associated with a risk of gastrointestinal bleeding, excessive alcohol intake may further increase this potential.


Q: What is the connection between Clopi and stents?

Clopidogrel is frequently used as part of dual antiplatelet therapy (DAPT) alongside aspirin for patients who have received a coronary stent. This practice is supported by evidence indicating it is intended to help prevent blood clots from forming inside the implanted stent.


Q: Are there any specific laboratory tests required when taking Clopi?

Based on clinical and regulatory guidance, routine laboratory monitoring like specific platelet function testing or genetic testing for the CYP2C19 enzyme is generally not recommended for most patients receiving standard treatment. Official guidelines indicate these specific tests are not standard for routine use.


Q: What organs does Clopi primarily affect?

Official pharmacological data indicates that Clopidogrel must first be converted into its active form, a process that primarily occurs in the liver using specific enzymes (CYP2C19). Its primary therapeutic effect is on platelets, which are components in the blood responsible for clotting.


Q: Is Clopi used for high blood pressure?

Clopidogrel is an antiplatelet drug used to prevent blood clots related to cardiovascular events. Official regulatory indications do not include the treatment of high blood pressure (hypertension).


Q: Can Clopi be crushed or split?

The tablet is film-coated, and the drug manufacturer does not provide information specifying whether the tablets can be crushed or split. Regulatory guidance typically notes that unscored tablets are generally not evaluated for splitting.


Q: Do people typically experience fatigue when starting Clopi?

Excessive tiredness or fatigue has been reported as a potential side effect of this medication. Official classification rates for this side effect may vary.


Q: What is the general success rate mentioned in clinical trials for Clopi?

Official summaries of clinical trials indicate that the medication has been associated with a relative reduction in the risk of a composite outcome (cardiovascular death, heart attack, or stroke) when compared to aspirin alone for certain high-risk populations. This reduction is measured as a relative rate, not a simple percentage success rate.


Q: How is Clopi typically stopped when treatment ends?

Official patient information warns against abruptly stopping the medication without consulting a healthcare provider first. Abruptly discontinuing the treatment can be associated with an increased risk of serious cardiovascular events, such as a heart attack or stroke.


Q: Why is Clopi sometimes given with other antiplatelet medicines?

This medication is often combined with other antiplatelet agents, most commonly aspirin, as part of Dual Antiplatelet Therapy (DAPT). This combination is typically used after acute cardiovascular events or procedures to provide a stronger overall anti-clotting effect.


Q: Can I drive or operate machinery while taking Clopi?

Official regulatory documents list dizziness and headache among the reported side effects. These reactions may affect a person's ability to drive or operate machinery. The prescribing information suggests caution if these effects occur.


Q: Does Clopi have a black box warning?

Yes, the FDA prescribing information includes a Boxed Warning that highlights specific safety concerns. This warning specifically addresses the fact that the drug may have reduced effectiveness in certain patients who are poor metabolizers of the CYP2C19 liver enzyme.


Q: How often do serious side effects occur with Clopi?

According to official regulatory documents, the frequency of serious side effects varies. For example, Intracranial bleeding is classified as Uncommon (occurring in less than 1 in 100 people), while the severe blood disorder Thrombotic Thrombocytopenic Purpura (TTP) is classified as Very Rare/Not Known.


Q: What evidence supports the use of Clopi for Peripheral Artery Disease (PAD)?

Clinical trial evidence supporting the use of Clopi indicated that the benefit in secondary prevention, which is the prevention of further events, appeared to be robust for patients with established peripheral artery disease (PAD). This evidence is cited in support of its use for this specific indication.


Q: What kind of patient monitoring is necessary when on Clopi?

Official guidelines indicate that routine blood tests to assess the drug's function (like platelet function tests) are generally not recommended for standard use. However, monitoring of blood parameters, such as a complete blood count (CBC), may be considered to observe for rare potential side effects like low platelet counts or anemia.

How should Clopi be stored and disposed of?

Clopidogrel (Clopi) tablets must be stored at controlled room temperature (20 C to 25 C), protecting the medicine from excess heat and moisture. The tablets should remain in the original container and be kept tightly closed when not in use. This medicine must be stored out of the sight and reach of children to prevent accidental ingestion.

For disposal, official guidelines recommend a drug take-back program as the preferred method for unused or expired tablets. If a take-back program is unavailable, Clopidogrel is not on the FDA flush list. The proper procedure is to mix the tablets with an undesirable substance, seal the mixture in a container, and discard it in the household trash. Personal information on the packaging should be removed before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clopi found in:

A-Z Index: